Early Data Suggest Novo Nordisk's Long-Acting Insulin DegludecOn Par With Sanofi's Lantus
This article was originally published in Pharmaceutical Approvals Monthly
Novo Nordisk has made a good start for its ultra-long acting insulin Degludec, with much-anticipated Phase II data released at the American Diabetes Association annual scientific sessions June 25 showing that Degludec is as good as Sanofi-Aventis's Lantus (insulin glargine). However, to unseat the market leader, the Danish firm will need to show its insulin analog is superior in either maintaining blood glucose control or reducing the incidence of hypoglycemia
You may also be interested in...
As it continues to diversify away from its juggernaut Lantus, Sanofi takes a chance on a potential first-in-class drug not yet through Phase II.
New head-to-head study against popular oral Januvia could bolster case for use as a second-line agent in diabetes, company says.
Novo Nordisk is confident that it can continue to generate strong growth from its leading diabetes franchise. Having exited oral anti-diabetics, it's betting on further innovation in insulin and on a strong entry into the GLP-1 analog space.